Byondis Appoints Christoph Korpus as CEO to Lead ADC Technology Platform Development
核心洞察
Byondis (搜索) B.V. has appointed Christoph Korpus, PhD, MBA as Chief Executive Officer, effective immediately, succeeding company founder Jacques Lemmens who remains as Chairman.
Korpus brings over 15 years of biopharmaceutical experience and will guide advancement of Byondis (搜索)' novel antibody-drug conjugate technology platforms including ByonGuard masking technology and ByonBoost immune-stimulatory platform.
The Netherlands-based company operates as a fully integrated biotech with over 200 staff and proprietary ADC platforms that combine novel payloads with advanced linker and conjugation technologies.
Byondis (搜索) B.V., an independent biopharmaceutical company focused on innovative targeted cancer medicines, announced the appointment of Christoph Korpus, PhD, MBA, as Chief Executive Officer, effective immediately. Korpus, who has served as Chief Business Officer since January 2025, succeeds company founder Jacques Lemmens, PhD, who will remain on the Board of Directors as Chairman.
Strategic Leadership Transition
The leadership change comes as Byondis (搜索) continues its strategic transformation into a focused, fully-integrated biotech company. According to Jacques Lemmens, Chairman of Byondis' Board of Directors, "Since joining as CBO last year, Christoph has been instrumental in driving Byondis' strategic transformation into a focused, fully-integrated biotech company with multiple proprietary ADC technology platforms and a wealth of clinical and manufacturing expertise."
Korpus brings more than 15 years of experience across the biopharmaceutical industry, spanning oncology R&D, digital innovation, and global business development and licensing. Prior to joining Byondis (搜索), he served as Director, Global Business Development and Licensing Oncology at Merck KGaA, where he led partnering strategies and negotiation teams for multiple oncology transactions.
Advanced ADC Technology Platforms
In his new role, Korpus will guide the advancement of research and development activities for Byondis (搜索)' novel antibody-drug conjugate (ADC) technology platforms. The company's platforms combine proprietary, novel payloads with state-of-the-art linker and conjugation technologies and conditional activation.
Byondis (搜索)' technology portfolio includes three key platforms:
- Cytotoxic antifolate linker-drug platform
- ByonGuard™ masking technology for conditional activation
- ByonBoost™ immune-stimulatory linker-drug platform
Each of these technology platforms has generated frontrunner and multiple follower drug candidates. The company maintains fully integrated discovery, development, and manufacturing capabilities, providing flexibility to conduct all essential development efforts for its lead candidates independently.
Future Strategic Vision
Korpus emphasized his commitment to leveraging the company's established strengths. "My focus now is executing our strategic vision, fostering partnerships that enhance our growth, and working with our talented team to deliver innovative ADC therapies that can overcome the critical limitations of current and next-generation therapies to make a meaningful difference for cancer patients," he stated.
The newly appointed CEO highlighted the company's readiness for growth, noting that "the path forward to maximize the value of our decades of ADC expertise is so clear." Under Lemmens' previous leadership, Byondis (搜索) built strong capabilities across ADC discovery and development and GMP manufacturing.
Company Infrastructure and Capabilities
Byondis (搜索) operates as a fully integrated biopharmaceutical research and development company with a dedicated team of more than 200 staff working in state-of-the-art R&D and GMP manufacturing facilities in Nijmegen, the Netherlands. The company's development portfolio leverages expertise in linker-drug technology, antibody-drug conjugation, and disease biology.
The company's fully integrated drug development capabilities cover all stages from pre-clinical and clinical R&D to production of clinical batches of selected product candidates and regulatory filings, all conducted in-house. Beyond internal development activities, Byondis (搜索) remains open to partnerships around its pipeline assets and licensing its technology for co-development opportunities.
Korpus holds a PhD from Ludwig-Maximilians-Universität Munich and the University of Connecticut, along with an MBA from the Kellogg School of Management at Northwestern University and the WHU-Otto Beisheim School of Management.